SHPHF (Sihuan Pharmaceutical Holdings Group) 3-Year Share Buyback Ratio: 1.00% (As of Dec. 2025) — 900% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHPHF Sihuan Pharmaceutical Holdings Group Ltd SHPHF
61 GF Score
Price $0.12
GF Value $0.17
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Sihuan Pharmaceutical Holdings Group 3-Year Share Buyback Ratio?

Sihuan Pharmaceutical Holdings Group SHPHF 61 3-Year Share Buyback Ratio is 1.00 as of Dec. 2025, which is 900% above its 10-year median of 0.10. GuruFocus rates SHPHF with a GF Score™ of 61/100 and a GF Value™ of $0.17 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 644 Drug Manufacturers companies, Sihuan Pharmaceutical Holdings Group ranks better than 91.77% on this metric.

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Sihuan Pharmaceutical Holdings Group's current 3-Year Share Buyback Ratio was 1.00%.

The historical rank and industry rank for Sihuan Pharmaceutical Holdings Group's 3-Year Share Buyback Ratio or its related term are showing as below:

SHPHF' s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -1.2   Med: 0.1   Max: 3
Current: 1

During the past 13 years, Sihuan Pharmaceutical Holdings Group's highest 3-Year Share Buyback Ratio was 3.00%. The lowest was -1.20%. And the median was 0.10%.

SHPHF's 3-Year Share Buyback Ratio is ranked better than
91.77% of 644 companies
in the Drug Manufacturers industry
Industry Median: -2 vs SHPHF: 1.00

Sihuan Pharmaceutical Holdings Group (OTCPK:SHPHF) 3-Year Share Buyback Ratio Explanation

A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.


Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.


Sihuan Pharmaceutical Holdings Group 3-Year Share Buyback Ratio Related Terms


SHPHF vs ZTS: 3-Year Share Buyback Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Sihuan Pharmaceutical Holdings Group's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sihuan Pharmaceutical Holdings Group 3-Year Share Buyback Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sihuan Pharmaceutical Holdings Group's 3-Year Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Sihuan Pharmaceutical Holdings Group's 3-Year Share Buyback Ratio falls into.


SHPHF
61GF Score
Sihuan Pharmaceutical Holdings Group Ltd SHPHF
3-Year Share Buyback Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sihuan Pharmaceutical Holdings Group 3-Year Share Buyback Ratio Calculation

This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

What does a 3-Year Share Buyback Ratio of 1.00 mean?
Sihuan Pharmaceutical Holdings Group (SHPHF) has a 3-Year Share Buyback Ratio of 1.00 as of Dec. 2025. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Sihuan Pharmaceutical Holdings Group and its competitors. This is 900% above median its historical median of 0.10. According to the industry distribution chart, Sihuan Pharmaceutical Holdings Group ranks #53 out of 644 companies in the Drug Manufacturers industry, placing it in the top 8.2%.
Is Sihuan Pharmaceutical Holdings Group's 3-Year Share Buyback Ratio too high?
Sihuan Pharmaceutical Holdings Group's current 3-Year Share Buyback Ratio of 1.00 is 900% above median its 10-year median of 0.10. Based on the distribution chart, Sihuan Pharmaceutical Holdings Group ranks #53 out of 644 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Sihuan Pharmaceutical Holdings Group has a GF Score™ of 61/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sihuan Pharmaceutical Holdings Group's 3-Year Share Buyback Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Sihuan Pharmaceutical Holdings Group ranks #53 out of 644 companies for 3-Year Share Buyback Ratio. This places Sihuan Pharmaceutical Holdings Group in the top 8% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Share Buyback Ratio for a Drug Manufacturers company?
A good 3-Year Share Buyback Ratio depends on the Drug Manufacturers industry context. However, 3-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Share Buyback Ratio mean?
A high 3-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Sihuan Pharmaceutical Holdings Group and its competitors. Sihuan Pharmaceutical Holdings Group's current 3-Year Share Buyback Ratio is 1.00, which is 900% above median its own 10-year median of 0.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sihuan Pharmaceutical Holdings Group stock overvalued right now?
Based on GuruFocus' analysis, Sihuan Pharmaceutical Holdings Group (SHPHF) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.17, compared to a current price of $0.12 — trading 29.4% below its estimated fair value. The current 3-Year Share Buyback Ratio is 1.00, which is 900% above median its 10-year median of 0.10. Sihuan Pharmaceutical Holdings Group's overall GF Score™ is 61/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Share Buyback Ratio calculated?
3-Year Share Buyback Ratio is calculated from a company's financial statements. For Sihuan Pharmaceutical Holdings Group (SHPHF), the current 3-Year Share Buyback Ratio is 1.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sihuan Pharmaceutical Holdings Group (SHPHF) Overvalued in 2026?

Based on GuruFocus' analysis, Sihuan Pharmaceutical Holdings Group stock appears to be undervalued. The current stock price of $0.12 is trading 29.4% below its estimated GF Value™ of $0.17. GuruFocus considers Sihuan Pharmaceutical Holdings Group to be Modestly Undervalued.

Key valuation signals for SHPHF:

  • 3-Year Share Buyback Ratio: 1.00 (900% above median its 10-year median of 0.10)
  • GF Value™: $0.17 vs. price of $0.12 (29.4% below fair value)
  • GF Score™: 61/100 with 4 warning signs

No single metric tells the full story. See the SHPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sihuan Pharmaceutical Holdings Group Business Description

Other Exchanges 00460:Hong KongTEL1:Germany
Address 1 Harbour Road, Convention Plaza, Room 4905, Office Tower, Wanchai, HKG
Sihuan Pharmaceutical Holdings Group Ltd is an investment holding company. Along with its subsidiaries, the company is engaged in the research & development and the manufacture & sale of pharmaceutical products. Its portfolio comprises products for diseases related to the cardio-cerebral vascular (CCV) system, Respiratory, Neurology, and others. The group has three reportable segments: the medical aesthetic products segment, including the filling, shaping, supporting, supplementing, optoelectronic device, body sculpturing, skincare, and others; the innovative medicine and other medicine segment; and the generic medicine segment, which generates key revenue. Geographically, the company generates a majority of its revenue from Mainland China and the rest from the United States.
61GF Score

Get the complete analysis for SHPHF

3-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.12
Price
$0.17
GF Value